Cancer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regarding antigen selection, strategy for immune stimulation, patient stratification, and monitoring of elicited response.
A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into these central issues.
Written by:
Dranoff G. Are you the author?
Department of Medical Oncology and Cancer Vaccine Center, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Reference: Cancer Cell. 2012 Sep 11;22(3):287-9.
doi: 10.1016/j.ccr.2012.08.021
PubMed Abstract
PMID: 22975372
UroToday.com Renal Cancer Section
